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Abstract
Rationale: Non–cystic fibrosis bronchiectasis is characterized by
airway mucus accumulation and sputum production, but the role of
mucus concentration in the pathogenesis of these abnormalities has
not been characterized.
Objectives: This study was designed to: 1) measure mucus
concentration and biophysical properties of bronchiectasismucus; 2)
identify the secreted mucins contained in bronchiectasis mucus; 3)
relate mucus properties to airway epithelial mucin RNA/protein
expression; and 4) explore relationships between mucus
hyperconcentration and disease severity.
Methods: Sputum samples were collected from subjects with
bronchiectasis,withandwithoutchronic erythromycinadministration, and
healthy control subjects. Sputum percent solid concentrations, total and
individualmucin concentrations, osmotic pressures, rheological properties,
and inflammatory mediators were measured. Intracellular mucins were
measured in endobronchial biopsies by immunohistochemistry and gene
expression. MUC5B (mucin 5B) polymorphisms were identified by
quantitative PCR. In a replication bronchiectasis cohort, spontaneously
expectorated and hypertonic saline-induced sputa were collected, and
mucus/mucin concentrations were measured.
Measurements and Main Results: Bronchiectasis sputum
exhibited increased percent solids, total and individual (MUC5B
and MUC5AC) mucin concentrations, osmotic pressure, and
elastic and viscous moduli compared with healthy sputum. Within
subjects with bronchiectasis, sputum percent solids correlated inversely
with FEV1 and positively with bronchiectasis extent, as measured by
high-resolution computed tomography, and inflammatory mediators.
No difference was detected inMUC5B rs35705950 SNP allele frequency
between bronchiectasis and healthy individuals. Hypertonic saline
inhalation acutely reduced non–cystic fibrosis bronchiectasis mucus
concentration by 5%.
Conclusions: Hyperconcentrated airway mucus is characteristic
of subjects with bronchiectasis, likely contributes to disease
pathophysiology, and may be a target for pharmacotherapy.
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Non–cystic fibrosis bronchiectasis (NCFB)
is characterized by persistent production of
purulent sputum, irreversible airway
dilatation, inflammation, and bacterial
infection. NCFB is commonly observed in
the middle and lower lobes, reflecting a
failure of mucociliary clearance and
gravity-dependent mucus accumulation (1).
NCFB can manifest as early and severe
mucopurulent obstruction in the small
airways, which can be difficult to recognize
radiographically (2). The pathogenesis of
the underlying mucus overproduction,
inflammation, and region-specific airway
damage in NCFB is poorly understood.
A unifying description of lung mucus
clearance in health and disease has emerged
that identifies mucus concentration as
central to mucoobstructive disease
pathogenesis (3). The “two-gel” hypothesis
predicts that when the concentration of the
mucus layer containing the secreted mucins
(MUC5B [mucin 5B] and MUC5AC)
exceeds that of the tethered mucin-
dominated periciliary layer (PCL), osmotic
compression of the cilia results (4). This
state produces mucus stasis and a positive
feedback cycle of inflammation and
mucus secretion (5). Recent studies
have demonstrated that the mucus
concentration, and proportionally mucin
concentration, of cystic fibrosis (CF)
sputum is on average threefold higher than
normal sputum (6, 7). The concentration of
mucins is also elevated in sputum samples
from subjects with chronic obstructive
pulmonary disease (COPD) and correlates
with increased disease severity and chronic
bronchitis symptoms (8). These and other
studies also established that the elevated
mucus concentrations of COPD and CF are
dominated by increases in MUC5B (7–9).
The only study of NCFB sputum mucin
content reported an unexpectedly high
concentration of the intestinal mucin
MUC2, less MUC5AC, and very little
MUC5B (10). Therefore, whether abnormal
airway mucus concentration or mucin
species expression is inherent to the
pathogenesis of NCFB is unclear.
Accordingly, we comprehensively
characterized sputum collected after
hypertonic saline (HS) induction from the
BLESS (Bronchiectasis and Low-Dose
Erythromycin Study) NCFB cohort,
composed of subjects with relatively severe
bronchiectasis (11), and compared these
data with healthy control subjects. The first
aim was to investigate whether mucus
concentration and biophysical properties,
including sputum percent solids, total
mucin concentration, osmotic pressure, and
elastic and viscous moduli, in BLESS sputa
were in ranges predicted to impair mucus
clearance. The second aim was to measure
the percent solids and total mucin
concentration in a replicate NCFB
cohort and compare concentrations of
spontaneously expectorated sputum with
sputum induced by HS inhalation. The
third aim was to measure the relative
concentrations of MUC5B, MUC5AC, and
MUC2 in NCFB versus control sputum.
The fourth aim was to relate mucus
properties to airway mucin RNA/protein
expression. Finally, we explored
relationships between the mucus
concentration data and data available in the
BLESS cohort describing NCFB disease
severity, cytokines, and MUC5B genotypes.
Some of the results of these studies have




Full details of the methods are provided in
the online supplement. This study was
approved by Mater Health Services (HREC
1244A) and University of North Carolina
at Chapel Hill (UNC) (#16-3142)
Human Research Ethics Committees,
and all subjects provided written
informed consent. In total, 117 subjects
with NCFB enrolled in the BLESS study,
who were extensively characterized
with spirometry, high-resolution CT,
and questionnaires (e.g., St. George’s
Respiratory Questionnaire), had HS-
induced sputum collected and immediately
aliquoted and frozen at 2808C after
discarding the material obtained during the
first 5 min of induction to reduce salivary
contamination (11). A subgroup of 34
BLESS subjects underwent bronchoscopy
(11). Twenty healthy control subjects
recruited from the community in
Queensland, Australia, also underwent
identical HS sputum induction and
bronchoscopy. Sputum samples collected
midway through the trial from 99 subjects
with NCFB were sent to UNC for mucus
analysis.
As a replication cohort, 15 subjects
with NCFB were recruited from the UNC
Bronchiectasis Centre, and 15 healthy
control subjects were recruited from the
local community in North Carolina.
Matched HS-induced and spontaneously
expectorated sputum were collected from
the subjects with NCFB in the UNC NCFB
cohort. HS-induced sputum only could be
collected from the UNC healthy subjects.
Mucus Percent Solids and Total,
Individual Mucin, and DNA
Concentrations
The percentage of mucus solid content, an
index of hydration, was calculated by
measuring dry-to-wet weight ratio of 25 ml
aliquots of sputum in triplicate using an
ultramicrobalance (UMX2; Mettler Toledo)
(4). Sputum total mucin concentrations
At a Glance Commentary
Scientific Knowledge on the
Subject: Non–cystic fibrosis
bronchiectasis (NCFB) is a chronic
airways disease characterized by
sputum production, persistent airway
inflammation, and repeated episodes
of disease exacerbation. Although
daily sputum volume and FEV1 may
be indicators of disease severity in
NCFB, the roles of mucus
concentration and biophysical
properties in disease pathogenesis
have not been elucidated.
What This Study Adds to the Field:
This study characterized the
concentration and biophysical
properties of sputum from subjects
with NCFB. NCFB sputa were
excessively concentrated compared
with healthy control subjects, with
higher percent solids and total mucin
concentrations. The biophysical
properties of NCFB sputa, for example,
osmotic pressures and elastic and
viscous moduli, were also increased
and positively correlated with sputum
concentration. MUC5B was the
dominant mucin raised in NCFB
sputum, with modest total elevations in
MUC5AC but little MUC2. The
magnitudes of the increases in mucus
concentration and biophysical values
suggest that mucus hyperconcentration
contributes to defective mucus
clearance and disease pathogenesis in
NCFB and may be a target for therapy.
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were measured by HPLC and refractometry
methods as previously reported (7).
Absolute concentrations of MUC5AC,
MUC5B, and MUC2 were measured by
labeled mass spectrometry in a subset of
sputum samples (n=33) (8). To assess the
charge status of MUC5AC and MUC5B,
agarose gel Western blotting was performed
(14). The DNA concentration of sputum was
quantified using a Quant-iT PicoGreen
dsDNA Assay Kit (ThermoFisher Scientific).
Mucus Osmotic Pressure and
Rheology
Sputum osmotic pressures were measured
using a custom-designed direct membrane
colloid osmometer incorporating a 10-kD
membrane as previously described (4). The
viscous and elastic moduli of sputum were





transbronchoscopic biopsies for MUC5AC
and MUC5B was performed as described
previously (16). A score from 0 to 4 was
assigned to the surface epithelium and
submucosal glands according to the
percentage of mucin-positive cells: 0 = no
staining, 1 = 1–25%, 2 = 26–50%,
3 = 51–75%, and 4 = 76–100%.
Gene Expression
Gene expression was measured in RNA
extracted from airway biopsies by
quantitative PCR. Details are provided in
the online supplement.
MUC5B Promoter SNP Genotyping
Assay
MUC5B promoter SNP (rs35705950)
genotype was determined using a TaqMan
SNP Genotyping Assay (Life Technologies).
Healthy individuals (n=575) were randomly
selected from the Queensland electoral roll.
Data Analysis
Data analysis for the BLESS clinical trial has
been described previously (11). As the
primary focus of this study was to examine
associations between mucus properties and
clinical outcomes in NCFB, data from the
placebo and treatment arms were grouped.
Mann-Whitney U and Kruskal-Wallis tests
were used to test the significance of variance
between control and disease groups. For
paired group comparisons, Wilcoxon signed-
rank tests were used. Results are presented in
median and interquartile range, and
correlations are presented with 95%
confidence interval, unless specified
otherwise. Correlations were calculated
using Spearman rho correlation coefficients.
Receiver operating characteristic curve
analysis was utilized to test the ability of
mucus properties to predict NCFB.
Statistical analyses were performed using
STATA (version 13.1) and GraphPad Prism
(version 7) software, where P values, 0.05
were considered significant.
Results
The demographic information for the NCFB
and healthy control subjects from the BLESS
and UNC cohorts is provided in Table 1.
The demographics for the full BLESS
cohort are provided in Table E1 in the
online supplement.
Mucus, Total Mucin, and DNA
Concentration
The mean mucus percent solids and
total mucin concentrations were
approximately threefold higher in sputum
from individuals with NCFB than in healthy
control subjects, respectively (P,0.001)
(Figures 1A and 1B and Table 1). Total DNA
concentrations were z20-fold higher in
subjects with NCFB than in control subjects
(Figure 1C). However, DNA concentrations
were z13-fold lower than total mucin
concentrations in subjects with NCFB
(P,0.001). Total mucin (Spearman rho
[95% confidence interval]=0.81 [0.73–0.88],
P,0.001) and DNA concentrations (0.72
[0.60–0.84], P,0.001) positively correlated
with mucus percent solids in patients with
NCFB (Figures 1D and 1E). Daily sputum
volume did not correlate with mucus percent
solids (Figure E1A), total mucin concentration,
or total DNA concentration.
Reproducibility of NCFB Mucus
Concentration and Effect of HS
Induction
The mucus percent solids (Figure 2A) and
total mucin content (Figure 2B) were not
different between HS-induced sputum
samples from BLESS and UNC subjects with
NCFB (also Table 1). However, sputum
induction with HS reduced the percent
solids and total mucin concentration z25%
compared with spontaneous sputum
samples collected in the same UNC subjects
with NCFB (Figure 2).
Table 1. Subject Demographics and Disease Characteristics of Patients with
Non–Cystic Fibrosis Bronchiectasis and Healthy Individuals Included in the Study
BLESS UNC
Bronchiectasis Healthy Bronchiectasis Healthy
Demographics
n 99 20 15 15
Age, yr, mean (6SD) 62 (610) 36 (612) 66 (613) 42 (619)
Sex, F, No. (%) 59 (60) 12 (60) 13 (86) 12 (80)
Lung function
measurements
FEV1, L, mean (6SD) 1.8 (60.7) 3.5 (60.8) 1.7 (60.7) 3.7 (60.8)
FEV1,% predicted, mean
(6SD)
66 (618) 98 (613) 69 (621) 100 (69)
Sputummicrobiology, No. (%)
Normal flora (no pathogens) 53 (45) 20 (100) 8 (53) NA
P. aeruginosa 41 (35) 0 3 (20) NA
H. influenzae 23 (20) 0 1 (7) NA
S. maltophilia 3 (2.6) 0 0 (0) NA
Others 5 (4.3) 0 3 (20) NA
Mucus parameters, median
(interquartile range)
Solids, % 2.7 (2.0) NA 2.6 (3.3) 1.0 (0.6)
Total mucins, mg/ml 4,594 (3,139) NA 3,951 (2,770) 1,820 (1,954)
Total DNA, mg/ml 279 (482) NA 213 (619) 9.2 (20.1)
Osmotic pressure, Pa 439 (362) NA 420 (537) 145 (72)
Complex viscosity, Pa $ s 0.2 (0.3) NA 0.2 (0.2) 0.1 (0.1)
Definition of abbreviations: BLESS=Bronchiectasis and Low-Dose Erythromycin Study; H.
influenzae=Haemophilus influenzae; NA=not applicable; P. aeruginosa=Pseudomonas aeruginosa;
S. maltophilia=Stenotrophomonas maltophilia; UNC=University of North Carolina at Chapel Hill.
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Mucin Subtypes
Mucin MUC5B concentrations were sixfold
higher in subjects with NCFB than in
healthy control subjects (Figure 3Ai).
Absolute MUC5AC concentrations were
17-fold higher in subjects with NCFB than
in healthy control subjects (Figure 3Aii).
The ratio of MUC5AC to MUC5B was
approximately fourfold higher in subjects
with NCFB (0.376 0.05) than in healthy
subjects (0.16 0.03). Label-free proteomics
revealed MUC2 concentrations were z100-
fold less than MUC5B or MUC5AC
(Figure 3Aiii). With respect to isoforms, the
low-charge isoform, but not high-charge
isoform, of MUC5B was significantly higher
in subjects with NCFB than in healthy
subjects (Figures 3B and 3C).
Sputum Biophysical Properties
The osmotic pressure of sputum from
healthy control subjects was z140 Pa,
similar to previously reported normal
values (Figure 4A) (7). In contrast, the
mean osmotic pressure of NCFB sputum
was z550 Pa, which was significantly
greater than control subjects (P, 0.01).
Sputum from patients with NCFB also had
higher elastic modulus (3.0-fold), viscous
modulus (2.8-fold), and complex viscosity
(2.3-fold) than healthy sputum (P, 0.01
each) (Figures 4B–4D). Sputum osmotic
pressure (Spearman rho [95% confidence
interval] = 0.71 [0.59–0.82], P, 0.001) and
complex viscosity (0.49 [0.32–0.66],
P, 0.001) positively correlated with mucus
percent solids (Figures 4E and 4F).
Similarly, osmotic pressure and complex
viscosity were positively associated with
total mucin and DNA concentrations
(P, 0.001 each) (Figures E1B–E1E).
Mucin Localization in Bronchial
Biopsies
In normal airways, scattered MUC5B
staining was observed in the superficial
epithelium in the absence of morphologic
goblet cells (not shown) (17, 18). In
contrast, mucus cells with a goblet cell
morphology containing both MUC5AC
and MUC5B were observed in NCFB
superficial airway epithelia (Figure E2A).
MUC5AC protein was not detected in the
submucosal glands of the healthy or NCFB
respiratory tract (Figure E2B). The
proportion of surface epithelial cells
expressing MUC5AC was significantly
higher in NCFB than in healthy epithelium
(P, 0.05) (Figure E2C). A trend to higher
surface epithelial expression of MUC5B was
observed in NCFB biopsies (P= 0.075).
Expression of Mucin and Mucus
Cell-Specific Genes
Despite the elevated sputum concentrations
of MUC5AC and MUC5B in subjects with
NCFB, expression of MUC5AC and
MUC5B mRNA in NCFB endobronchial
biopsies was not higher than healthy
control subjects (Figure E3). MUC2 mRNA
expression was low in healthy control
subjects and significantly reduced in NCFB
(P, 0.05), consistent with the low levels
of MUC2 protein in NCFB sputum
(Figure 3Aiii). The gene encoding a cell
surface mucin, MUC4, was also
downregulated in NCFB (P, 0.01),
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Figure 1. The biochemical properties of induced sputum from individuals with non–cystic fibrosis bronchiectasis (NCFB) and healthy control subjects. (A)
Mucus percent solids, (B) total mucin concentrations, and (C) extracellular DNA concentration were each significantly higher in individuals with NCFB (gray
circles) than in healthy control subjects (white circles). (D) Total mucin (Spearman rho [95% confidence interval] = 0.81 [0.73–0.88], P,0.001) and (E)
extracellular DNA concentrations (Spearman rho [95% confidence interval] = 0.72 [0.60–0.84], P,0.001) correlated significantly with mucus percent
solids (NCFB: gray circles; control subjects: white circles). (A–C) Individual data points, median, and interquartile ranges are shown; Mann-Whitney
nonparametric test was used. n=99 subjects with NCFB for all panels; n=15 healthy control subjects; ****P,0.0001. wt =weight.
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expression of genes encoding the other
major airway tethered mucins, that is,
MUC1 and MUC16. Genes encoding
proteins specifically expressed in mucin-
secreting cells, for example, TFF1, TFF3,
and AGR2, were upregulated in subjects
with NCFB compared with healthy control
subjects (by sevenfold, threefold, and
twofold, respectively), whereas expression
of TFF2, SPDEF, and ZG16B was not
significantly changed (Figure E3).
IPF-associated MUC5B
Polymorphism
The IPF risk allele (T) frequency of
rs35705950 in 101 BLESS subjects with
NCFB did not differ from 575 population
control subjects (10.90% and 10.95%,
respectively) (Table E2). Within the NCFB
cohort, carriage of the T allele was not
associated with any sputum or clinical
NCFB parameter.
Association between Sputum
Properties and Clinical Outcomes in
NCFB
The severe clinical features of the BLESS cohort
are not representative of the broad NCFB
populations and limit the sensitivity of
exploratory analyses relating mucus properties
to clinical parameters (11). However,
associations of mucus properties were sought
with respiratory symptoms (see online
supplement) and clinical parameters obtained
per the BLESS protocol.
Lung function and high-resolution chest
computed tomography. Within BLESS
subjects with NCFB, the FEV1 correlated
inversely with high-resolution chest computed
tomography (HRCT) bronchiectasis extent
score, suggesting both describe NCFB severity
(Figure 5A). Similarly, mucus concentration
was inversely correlated with FEV1
(Figure 5B). Mucus concentration was
positively correlated with the bronchiectasis
extent score (Figure 5C), whereas daily sputum
volume and mucus osmotic pressure were less
strongly correlated with the bronchiectasis
score (Table 2). No correlations were observed
between total mucins, sputum volume, and
FEV1 (not shown).
Inflammation. In subjects with NCFB,
IL-8 and IL-b concentrations and neutrophil
elastase and matrix metalloproteinase
activities were associated with sputum
percent solids, total mucin concentration,
MUC5AC/MUC5B ratio, daily sputum
volume, FEV1, and HRCT scores (Figures
5D and 5E and Table 3).
Pathogens. NCFB sputum mucus and
mucin concentrations were independent of
cultured pathogenic microorganisms, including
Pseudomonas aeruginosa (Figure E1F).
Ability of Percent Solids to Predict
NCFB
ROC analysis was performed to test the
ability of sputum percent solids to predict
NCFB (Figure 5F). We generated an
ROC for percent solids (continuous)
utilizing data from all subjects with
NCFB versus healthy control subjects. The
area under the curve was 0.9603. To
determine the cutoff value for percent
solids that maximized sensitivity and
specificity, we used the Youden’s index
(sensitivity1 specificity2 1), which yielded
a percent solids value of 1.62%.
Discussion
Dilated NCFB airways are characterized by the
accumulation of inflamed mucus. Our study
sheds light on the key constituents of NCFB
mucus, its regulation, and relevance to NCFB
pathogenesis. NCFB sputa were abnormally
concentrated as evidenced by higher percent
solids and total mucin concentrations than
healthy subjects. These findings were replicated
in a second NCFB cohort. Elevations in both
MUC5B andMUC5ACairwaymucins, but not
MUC2, contributed to the raised percent
solids/total mucin concentrations in the
subjects with NCFB. Elevated mucus
concentrations in NCFB were reflected in
classic measures of sputum biophysical
properties, including sputum viscosity,
elasticity, and complex viscosity. Importantly,
the increase in mucus concentration was also
reflected in elevated mucus osmotic pressure in
patients with NCFB.
Impairment of mucus transport occurs
when the mucus layer osmotic pressure
exceeds that of the PCL (4). The osmotic



















































Figure 2. Mucus percent solids and mucin concentration in induced and spontaneously expectorated sputum from individuals with non–cystic fibrosis
bronchiectasis from BLESS (Bronchiectasis and Low-Dose Erythromycin Study) (n=99) and the University of North Carolina at Chapel Hill (UNC) Hospitals
(n=15). There were no differences in the (A) mucus percent solids or (B) total mucin concentration in induced sputum samples from individuals with
bronchiectasis from the BLESS study and induced sputum samples from individuals with bronchiectasis at UNC Hospitals. Hypertonic saline–induced
sputum samples had significantly lower mucus percent solids and total mucin concentrations than spontaneously expectorated sputum samples from the same
individuals with bronchiectasis recruited from UNC Hospitals. Statistics: bars represent median and interquartile range; Mann-Whitney nonparametric test
was used; *P,0.05. wt =weight.
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studied were in a range predicted to
compress the PCL, slow mucus transport,
and contribute to mucoobstructive disease
pathogenesis. Indeed, significant associations
were observed between mucus concentration
and indices of disease severity, for example,
FEV1 and HRCT, in patients with NCFB.
These data are consistent with the nonlinear
relationships between mucus concentration
and mucus transportability (4) and indicate
a role for mucus concentration in the
mucoobstructive component of NCFB.
Notably, NCFB sputum total mucin
concentrations were z2 times higher than
sputum concentrations of sputum from
highly obstructed subjects with COPD,
consistent with the more severe
bronchiectatic lung disease characteristic
of NCFB versus COPD (19).
Analyses of individual secreted mucins
in NCFB sputum revealed several key
points. First, like previous reports, the
sputum MUC5B concentration in healthy
subjects was z10-fold greater than
MUC5AC (8). Second, consistent with
elevated total mucins in NCFB, the
concentrations of both major secreted
airway mucins, that is, MUC5AC and
MUC5B, were higher in NCFB than in
healthy control subjects. As reported
previously in COPD, the ratio of MUC5AC
to MUC5B concentrations was elevated in




























































































MUC5B LCI MUC5B HCI
Control
Bronchiectasis
Figure 3. Mucin glycoproteins in induced sputum from individuals with non–cystic fibrosis bronchiectasis and healthy control subjects. (A) Quantification
of MUC5B (mucin 5B) (Ai) and MUC5AC (Aii) by internal standard labeled mass spectrometry and comparisons of MUC2 to MUC5AC and MUC5B by
peptide intensity (Aiii). (B) Representative blots after agarose gel electrophoresis of denatured and reduced proteins extracted from sputum showing
staining of all mucins with periodic acid–Schiff (PAS) staining and immunoblotting for MUC5AC and MUC5B (LCI = low-charge isoform; HCI = high-charge
isoform). Note that the band pattern of the combined MUC5AC/MUC5B overlay (bottom panel) matches exactly with that in the PAS blot (top panel) for
each sample. (C) Quantification of HCI and LCI of MUC5B from agarose gel electrophoresis blots. Statistics: box-and-whisker plots display median,
interquartile ranges, and range; Mann-Whitney nonparametric test was used; ****P,0.0001. LFQ= label-free quantification; tot = total.
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compared with control subjects (8).
However, the concentration of MUC5B
exceeded the concentration of MUC5AC in
patients with NCFB. Thus, similar to
COPD, NCFB is a MUC5B-dominated
disease. Also like COPD, the MUC5B
promoter polymorphism associated with
increased MUC5B expression in IPF was
not associated with NCFB or NCFB disease
severity in the BLESS cohort (20).
We detected only very small
concentrations of MUC2 in normal and
NCFB sputa by mass spectroscopy. These
data contrast to the Sibila and colleagues
study that reported MUC2 was the
dominant mucin in NCFB, MUC2
concentrations correlated with
P. aeruginosa infection, and MUC5B was
nondetectable in 96% of NCFB samples
(10). We speculate that the discrepancies in
results reflect methodologic deficiencies in
the Sibila study, including: 1) sample
ultracentrifugation with only the soluble
fraction assayed, effectively removing the
highly gelled mucin glycoproteins and
underestimating mucin concentrations; and
2) use of commercial ELISA kits for the
mucin measurements without verification
of specificity or intactness of mucin
epitopes (7). Our data using multiple
independent physical and mass
spectroscopy-based methods indicate that
MUC5B and MUC5AC are the major
secreted mucins in patients with NCFB.
Elevated sputum volumes with
increased mucus concentrations in NCFB
imply increased mucus and mucin
production compared with healthy control
subjects. We have previously reported that
subjects with NCFB exhibit an increase in a
broad spectrum of cytokines in BAL fluid
(21). IL-1b is a major regulator of both
MUC5B and MUC5AC mucin in CF
airways (5), and both sputum IL-1b and the
chemokine IL-8 positively correlated not
only with sputum volume but also mucus
concentration. These findings, combined
with the associations of mucus
concentration with human neutrophil
elastase and matrix metalloproteinase,
suggest that multiple inflammatory
pathways participate in positive feedback
cycles to drive increased mucin biosynthesis
and, ultimately, mucus/mucin secretion (5).
Interestingly, P. aeruginosa infection was
not associated with mucus concentration,
suggesting that if bacteria also drive mucin
secretion, anaerobes and Haemophilus
influenzae may be sufficient.
Mucus concentration reflects the balance
betweenmucin and fluid (hydration) transport
rates. Typically, mucins are cosecreted with
paracrine/autocrine factors, for example,
purine nucleotides, that match fluid transport
to mucin secretory rates (3, 22, 23). As one
test of the role of mucin hypersecretion as
a contributor to raised NCFB mucus
concentrations, MUC5B and MUC5AC RNA
levels in bronchial biopsies were measured
and found not raised in NCFB compared
with healthy subjects. This observation was
juxtaposed to the increased goblet cell
numbers, secretory genes expressed in goblet
cells, and increased intracellular mucin stores
typically associated with increased sputum
volume. Presumably, this disconnect reflects:
1) the importance of post-transcriptional
regulation of mucin protein production rates;
and/or 2) the failure to adequately adjust
mucin RNA levels to mucin cell-specific
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Figure 4. The biophysical properties of induced sputum in individuals with non–cystic fibrosis bronchiectasis (NCFB). (A) Osmotic pressure, (B) viscous moduli,
(C) elastic moduli, and (D) complex viscosity of induced sputum were higher in individuals with NCFB (gray circles) than in healthy control subjects (white circles).
The (E) osmotic pressure (Spearman rho [95% confidence interval] =0.71 [0.59–0.82], P,0.001) and (F) complex viscosity (0.49 [0.32–0.66], P,0.001) of
induced sputum correlated significantly with mucus percent solids (NCFB: gray circles; control subjects: white circles). Dashed line/PCL=periciliary layer osmotic
pressure. (A–D) Individual data points, median, and interquartile ranges are shown; Mann-Whitney nonparametric test was used. n=99; **P,0.01 and
****P,0.0001. G=viscous modulus; wt=weight.
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b-ENaC mice, reduction in hydration, rather
than mucin hyperproduction/secretion, drives
the increase in mucus concentration (24, 25).
There are several mechanisms that may
generate a mismatch between active airway
transepithelial Na1 absorption versus Cl2
secretion that would produce a deficiency of
fluid on NCFB airway surfaces, that is,
dehydration. Recent in vitro studies have
reported that normal airways respond to
infection-related bacterial/host materials with
increased mucin production/secretion and
disproportionately raised Cl2/fluid secretion,
producing a reduction in mucus concentrations
(26). Subjects with bronchiectasis without
CFTR (cystic fibrosis transmembrane
conductance regulator) mutations are reported
to exhibit normal CFTR function, suggesting
NCFB epithelium should respond similarly to
epithelia from normal subjects (27). Three
complementary mechanisms may account for
abnormal fluid secretion in bronchiectatic
airways. First, adherent mucus produces local
epithelial hypoxia, which may inhibit CFTR
transcription/activity and limit fluid secretion
(28, 29). Second, aberrant extracellular
nucleotide/nucleoside-dependent airway
hydration mechanisms have been reported
in COPD that perturb the balance of Na1
absorption versus Cl2 secretion and
produce mucus hyperconcentration (30).
Chronic injury and inflammation in NCFB
may produce similar abnormalities. Third,
abnormal extracellular protease, for
example, human neutrophil elastase,
activation of ENaC activity has been
reported (31), which may also tip the
balance of fluid homeostasis toward
absorption in NCFB. This latter mechanism
is consistent with our data describing





Mucus concentration (% wt)














Mucus concentration (% wt)




























































0 5 10 15




















0 2 4 6 8 10
Mucus concentration (% wt)
C
Figure 5. Association between mucus percent solids and clinical outcomes in BLESS (Bronchiectasis and Low-Dose Erythromycin Study) subjects with
non–cystic fibrosis bronchiectasis (NCFB). (A) The high-resolution chest computed tomography bronchiectasis extent score significantly correlated with
FEV1 (Spearman rho [r] [95% confidence interval (CI)] = 0.40 [20.61 to 20.19], P,0.001). (B) FEV1 significantly correlated inversely with mucus percent
solids (r [95% CI] =20.22 [20.43 to20.01], P=0.03), and (C) mucus concentration correlated positively with high-resolution chest computed tomography
extent scores (r [95% CI]= 0.41 [0.19–0.63], P,0.001). Mucus percent solids was significantly associated with the concentration of (D) IL-8 (r [95% CI]= 0.48
[0.32–0.64], P,0.001) and (E) IL-1b (r [95% CI]= 0.40 [0.22–0.56], P,0.001) in sputum. (F) Ability of mucus concentration (percent solids) to diagnose
NCFB. Area under the receiver operating characteristic (ROC) curve=0.9603. Area under the ROC curve for total mucins in NCFB versus control
cohorts =0.949 (see Figure E5). wt=weight.
Table 2. Correlation between Sputum Mucus Properties and Lung Function and
Bronchiectasis Extent Score in Patients with Non–Cystic Fibrosis Bronchiectasis
FEV1 (% Predicted) Bronchiectasis Extent Score
Solids, % 20.22 (20.43 to 20.01)* 0.41 (0.19 to 0.63)†
Total mucins, mg/ml 20.08 (20.29 to 0.13) 0.10 (20.14 to 0.33)
MUC5AC/MUC5B 20.43 (20.74 to 20.12)* 0.22 (20.20 to 0.63)
Sputum volume, g 20.20 (20.40 to 0.002) 0.35 (0.13 to 0.57)‡
Osmotic pressure, Pa 20.01 (20.22 to 0.21) 0.25 (0.002 to 0.50)*
Complex viscosity, Pa $ s 0.08 (20.16 to 0.31) 0.26 (0.02 to 0.51)*
Definitions of abbreviations: MUC5AC=mucin 5AC; MUC5B=mucin 5B.
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concentrations of neutrophil elastase and
matrix metalloproteinase and sputum
mucus and mucin concentrations.
The severity of the BLESS cohort made
searching for sputum biomarkers to describe
NCFB severity difficult. The heterogeneity
of disease within lungs of subjects with
NCFB also complicates the utility of sputum
as a biomarker. However, recent data
suggest that mucus is only spontaneously
expectorated as sputum when it is
abnormally hyperconcentrated (32).
Consequently, a single, but severely
diseased (bronchiectatic) region with
hyperconcentrated mucus can lead to
production of sputum that may contain
diagnostic information (32). This
consideration, coupled to the severity of the
BLESS population, likely contributed to the
“excellent” area under the curve observed in
the utility of ROC analyses of sputum
percent solids to discriminate between
NCFB versus control subjects. As
disease progresses, more areas become
bronchiectatic, and spirometry becomes
abnormal. Interestingly, sputum volume,
which might also be expected to reflect
disease severity within the NCFB cohort,
did not correlate with FEV1. However,
modest associations of mucus percent
solids with FEV1 were observed, suggesting
NCFB disease progression may be
associated with intensification of
the processes that produce mucus
hyperconcentration. This notion is
consistent with observations that mucus
percent solids and osmotic pressure also
correlated with HRCT in BLESS subjects.
These correlations mimic previous reports
that total mucins were inversely associated
with FEV1 in chronic bronchitis, where
mucus hyperconcentration is also present
(33). Collectively, these data suggest that
mucus concentration may be an excellent
biomarker for the presence of NCFB
disease and a modest biomarker for NCFB
disease extent/progression.
Although macrolides reduce
exacerbations, reduce sputum volume, and
improve lung function in patients with
NCFB, their mechanisms of action remain
unclear (34). Macrolides have been shown
to have antimicrobial, including effects on
P. aeruginosa quorum sensing (35), and
immunomodulatory properties (36). In the
BLESS trial, erythromycin induced a rapid
and sustained decline in daily sputum volume
(11). Our study was not designed to test
whether erythromycin produced changes in
sputum concentration or composition from
baseline values. Hence, our study does add
to mechanistic insights into macrolide
mucoregulatory activities in NCFB. However,
our study did reveal that HS sputum
induction reduced sputum mucus
concentrations by z25%. These data suggest
the HS may have a favorable mechanism of
therapeutic action, that is, rehydrate/dilute
hyperconcentrated mucus. Whether the likely
short duration of action of inhaled HS in
non-CF lung disease can produce therapeutic
activity is unknown (37).
Strengths of our study include its setting
within a large trial-based cohort with
extensive clinical characterization, a healthy
control comparator cohort, a replicate disease
cohort, endobronchial samples, longitudinal
data, and parallel measurements of microbial
status and inflammation. There are also
inherent limitations of our study. BLESS
subjects were selected on the basis of high
exacerbation frequency and are skewed
toward a severe phenotype. Induced sputum
samples were evaluated, as they provide
reliable samples of both healthy and diseased
airways, but we showed that induction
produced modest sputum dilution. Rheology
was performed on small aliquots that were
subject to freeze–thaw, which had the
potential to influence the biophysical data.
The MUC5B SNP analysis was performed
on only 101 patients with bronchiectasis,
which is a small sample size for a
polymorphism study. Finally, bronchial
biopsies were obtained from subsegmental
carinas, which may not reflect gene
expression in diseased, that is, ectatic,
airways.
In summary, similar to other
mucoobstructive airway diseases, NCFB
sputum exhibits elevated mucus percent
solids, total and individual mucin
concentrations, mucus osmotic pressures,
and mucus viscoelastic moduli compared
with sputum from healthy control subjects.
The alterations in mucus properties appear
to be influenced by the severity of airway
inflammation, but not the presence of
classical pathogens. The level of mucus
concentration in patients with NCFB is
within the range predicted to produce
mucostasis and reductions in FEV1. These
observations suggest that rehydration of
NCFB airways may be a rational
therapeutic strategy. n
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Table 3. Correlation between Sputum Mucus Properties and Inflammatory Markers in Patients with Non–Cystic Fibrosis
Bronchiectasis
IL-8 (ng/ml) IL-1b (pg/ml) NE Activity (mg/ml) MMP Activity (AU/ml)
Solids, % 0.48 (0.32 to 0.64)* 0.40 (0.22 to 0.56)* 0.47 (0.30 to 0.63)* 0.53 (0.37 to 0.70)*
Total mucins, mg/ml 0.36 (0.18 to 0.55)* 0.27 (0.06 to 0.48)* 0.29 (0.10 to 0.48)† 0.35 (0.15 to 0.54)†
MUC5AC/MUC5B 0.49 (0.14 to 0.84)† 0.57 (0.28 to 0.85)† 0.45 (0.18 to 0.72)† 0.49 (0.18 to 0.79)‡
Sputum volume, g 0.26 (0.04 to 0.48)‡ 0.35 (0.12 to 0.58)† 0.29 (0.08 to 0.51)† 0.30 (0.08 to 0.51)†
Osmotic pressure, Pa 0.26 (0.04 to 0.49)‡ 0.08 (20.14 to 0.29) 0.15 (20.07 to 0.37) 0.15 (20.07 to 0.38)
Complex viscosity, Pa $ s 0.32 (0.11 to 0.54)† 0.23 (0.01 to 0.46)‡ 0.21 (20.003 to 0.44) 0.24 (0.04 to 0.44)‡
FEV1, % predicted 20.25 (20.46 to 20.03)
‡ 20.28 (20.49 to 20.07)† 20.39 (20.58 to 20.19)* 20.44 (20.63 to 20.26)*
Bronchiectasis score 0.49 (0.30 to 0.69)* 0.46 (0.26 to 0.65)* 0.56 (0.36 to 0.76)* 0.63 (0.47 to 0.76)*
Definition of abbreviations: MMP=matrix metalloproteinase; MUC5AC=mucin 5AC; MUC5B=mucin 5B; NE=neutrophil elastase.
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